Biotest acts on an international level: we sell our products in more than 85 countries worldwide – in many cases, we have already done so for decades. Our sites in Europe, in the U.S. and in Asia make us a Global Player.

Biotest products enjoy worldwide distribution – in Asia, Africa, America and Europe, we are represented in many markets by leading suppliers. Our plasma proteins products are under supervision of government boards, and they need regulatory approval. Therefore, knowing the respective legal provisions is crucial for our business activities. In ten countries, we have our own marketing organisations that do not only ensure proximity to our most important clients, but also keep close contact to the national regulatory agencies. In other states, we work in co-operation with sales partners who have committed themselves to the quality standards of Biotest.
 
Many of our plasma proteins have already obtained regulatory approval in all important European markets. By additional regulatory approvals, we will gradually expand the sales basis for those products. Since the end of 2007, we are also strongly represented in the U.S. Our subsidiary Biotest Pharmaceuticals Corp. (BPC) manufacturers and distributes immunoglobulins. Furthermore, it has promising new products in its pipeline. The most interesting among those is, above all, a polyspecific intravenous immunoglobulin, which we develop with high priority to obtain market approval. 
 
BPC provides the platform for the further expansion of our presence in this highly attractive market. In addition, the precursor products and intermediates made in the USA can be used for manufacturing in Dreieich. The cooperative manufacturing linkage newly established between Dreieich and Boca Raton will boost efficiency.
 
The U.S. are also in the focus of our strategy that is aimed at further developing our diagnostics business. In parallel, we likewise strive to grow within the European sector of this business activity as well as to open up the potential of the Asian markets.
 
Almost fifty percent of our staff works outside Germany, the U.S. being the next important site after our mother country. Our internal structures – e.g. in Human Resources and in the Group organisation – are adapted to this situation.